Outcome statement - February 2024 DUSC meeting

22 March 2024 - The Outcome Statement from the February 2024 DUSC meeting is now available. ...

Read more →

More rare conditions considered for newborn bloodspot screening and new treatment option for spinal muscular atrophy

29 February 2024 - On Rare Disease Day, the Albanese Government has announced two more rare genetic conditions have been ...

Read more →

Outcomes from the December 2023 PBAC intracycle meeting

25 January 2024 - The outcomes from the December 2023 PBAC intracycle meeting are now available. ...

Read more →

Recommendations made by the PBAC (November 2023)

18 December 2023 - Recommendations made by the PBAC in November 2023 relating to the listing of medicines on the ...

Read more →

Outcomes of the September 2023 PBAC intracycle meeting

13 October 2023 - The outcomes from the September 2023 PBAC intracycle meeting are now available. ...

Read more →

Australia knocks back application for diabetes drug that could overshadow Ozempic

29 August 2023 - Australia has knocked back an application to subsidise the diabetes drug Mounjaro but the manufacturer still wants ...

Read more →

Recommendations made by the PBAC (July 2023)

18 August 2023 - Recommendations made by the PBAC in July 2023 relating to the listing of medicines on the ...

Read more →

Estimating overall survival in people receiving PBS listed cancer medicines in Australian clinical practice

18 August 2023 - In September 2021, the Department of Health and Aged Care contracted the Medicines Intelligence Centre for ...

Read more →

Outcome statement - June 2023 DUSC meeting

18 July 2023 - The outcome statement from the June 2023 DUSC meeting is now available. ...

Read more →

Changes to PBS eligibility criteria for Paxlovid

23 June 2023 - In an out of session consideration, the PBAC has recommended changes to the circumstances under which nirmatrelvir ...

Read more →

Outcomes of the May 2023 PBAC intracycle meeting

16 June 2023 - The outcomes from the May 2023 PBAC intracycle meeting are now available. ...

Read more →

Revolutionising MS treatment: new form of Tysabri recommended for PBS listing

24 May 2023 - The PBAC has recommended the listing of natalizumab (Tysabri) pre-filled syringe for subcutaneous injection on the PBS.  ...

Read more →

Outcome in relation to fluticasone propionate – May 2023 PBAC intracycle meeting

12 May 2023 - The outcome for fluticasone propionate from the May 2023 PBAC meeting is now available. ...

Read more →

Recommendations made out-of-session by the PBAC between March 2023 and July 2023 meetings

10 May 2023 - Recommendations made out-of-session by the PBAC between its March 2023 and July 2023 meetings are now available. ...

Read more →

Recommendations made by the PBAC (March 2023)

21 April 2023 - Recommendations made by the PBAC in March 2023 relating to the listing of medicines on the Pharmaceutical ...

Read more →